# i&i Biotech Fund

> i&i Biotech Fund is a VC fund in Luxembourg backing Biotechnology and Medical. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Luxembourg, Luxembourg
- Total investments: 16
- Last investment: Mar 2026
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/i-i-biotech-fund/
- Website: https://www.inibio.eu/

i&i Biotech Fund (i&i Bio) is a Luxemburg-based venture capital firm that invests in innovative European Life Science companies focused on drug discoveries, medical devices, diagnostics, and digital health.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $369k–$5.3M |
| Series A | $5.8M–$20M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 56% |
| Medical | 4 | 25% |
| Health Care | 4 | 25% |
| Life Science | 2 | 13% |
| Pharmaceutical | 2 | 13% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 56% |
| Series A | 4 | 25% |
| Pre-Seed | 1 | 6% |
| Funding Round | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 3 | 19% |
| Czech Republic | 2 | 13% |
| United Kingdom | 2 | 13% |
| India | 1 | 6% |
| Spain | 1 | 6% |

8 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Theorema | Theorema.ai is an AI-powered startup that focuses on autonomous R&D agents for science-intensive industries, including innovative materials, biotech, pharmaceuticals, and chemicals. | $3.3M | Pre-Seed | Mar 27, 2026 |  |
| Ternary Therapeutics | Ternary Therapeutics is a biotechnology research center that specializes in bioinformatics and medicinal chemistry services. | $4.8M | Seed | Mar 16, 2026 |  |
| Antiverse | Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M | Series A | Mar 03, 2026 |  |
| T-CURX | T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care. | $20M | Series A | Dec 17, 2025 |  |
| Captain T Cell | Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates. | $23.2M |  | Nov 17, 2025 |  |
| KyDo Therapeutics | KyDo Therapeutics is a biotechnology company that develops novel covalent-allosteric small molecule inhibitors. | $5.3M | Seed | Sep 16, 2025 |  |
| Antiverse | Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $4.6M | Seed | Oct 15, 2024 |  |
| Captain T Cell | Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates. | $9.2M | Seed | May 22, 2024 |  |
| Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.7M | Seed | Jan 30, 2024 |  |
| HeartBeat.bio | HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies. | $4.8M | Seed | Nov 02, 2023 |  |

10 of 16 investments shown.

## Co-investors
- [KHAN Technology Transfer Fund](https://shizune.co/investors/profile/khan-technology-transfer-fund) — VC Fund, 5 deals together
- [i&i Prague](https://shizune.co/investors/profile/i-i-prague) — VC Fund, 3 deals together
- [Brandenburg Kapital](https://shizune.co/investors/profile/bfb-brandenburg-kapital-gmbh) — VC Fund, 2 deals together
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund, 2 deals together
- [Hil-Invent](https://shizune.co/investors/profile/hil-invent) — VC Fund, 2 deals together
- [Innospark Ventures](https://shizune.co/investors/profile/innospark-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Reflex Capital](https://shizune.co/investors/profile/reflex-capital) — VC Fund
- [MITON](https://shizune.co/investors/profile/miton-cz-s-r-o) — VC Fund
- [N1](https://shizune.co/investors/profile/nation-1) — VC Fund

## Featured in investor lists
- [Medical Investors in Czech Republic](https://shizune.co/investors/medical-investors-czech-republic)
- [Medical VC Funds in Czech Republic](https://shizune.co/investors/medical-vc-funds-czech-republic)
- [Health Care Investors in Czech Republic](https://shizune.co/investors/health-care-investors-czech-republic)
- [Health Care VC Funds in Czech Republic](https://shizune.co/investors/health-care-vc-funds-czech-republic)
- [All Investors in Czech Republic](https://shizune.co/investors/investors-czech-republic)
- [All VC Funds in Czech Republic](https://shizune.co/investors/vc-funds-czech-republic)

## FAQ

### What does i&i Biotech Fund invest in?

i&i Biotech Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 16 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is i&i Biotech Fund's check size?

i&i Biotech Fund typically joins rounds of $369k–$5.3M at Seed and $5.8M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds i&i Biotech Fund participates in.

### When did i&i Biotech Fund last invest?

The most recent investment recorded for i&i Biotech Fund closed in Mar 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co